We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics

Olympus

Manufactures optical and digital equipment for the healthcare and consumer electronics sectors, including endoscopy a... read more Featured Products: More products

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
24 Jan 2022 - 27 Jan 2022

AI-Based Pathology Diagnostic Tool for Gastric Cancer Achieves 100% Sensitivity in Trials

By LabMedica International staff writers
Posted on 29 Nov 2021
Print article
Image: Olympus AI-based pathology diagnostic tool (Photo courtesy of Olympus)
Image: Olympus AI-based pathology diagnostic tool (Photo courtesy of Olympus)

Olympus Life Science (Waltham, MA, USA) has announced the results of its ongoing joint research program to create an AI-based pathology diagnostic tool with the potential to streamline pathologists’ workloads. The diagnostic tool achieved 100% sensitivity and 50% or more specificity for all gastric biopsy pathology specimens analyzed.

The ongoing shortage of pathologists has led to a demand for AI-based pathology diagnostic tools. Olympus, through its Office of Innovation, began developing an AI-based pathology diagnostic tool. In the initial testing phase, the AI was trained using 368 gastric biopsy pathology slide images. The second phase of research began in November 2020, when the diagnostic tool was expanded to six hospitals in Japan, with the aim of verifying the versatility and improving the accuracy of the AI tool. Specifically, it was important to test whether the tool works correctly on pathology slides that vary in thickness and color. The goal of this program is to deliver AI pathology diagnosis software that can assist pathologists by 2023.

The AI-based pathology tool uses a convolutional neural network6 (CNN) optimized to analyze pathology images. This technology enables the tool to identify adenocarcinoma7 versus non-adenocarcinoma tissue in an image. Once the AI was trained, it was tested using 1200 pathology whole slide images from the six institutions participating in the study. The AI classified each image as either adenocarcinoma or non-adenocarcinoma. The AI tool was able to achieve 100% sensitivity and 50% or higher specificity for slides from all six facilities. The robustness of the results will enable Olympus to pursue commercialization of the AI tool in the future.

Related Links:
Olympus Life Science 

Gold Supplier
BMP Whole Blood Analyzer
GEM Premier ChemSTAT
New
Atomic Fluorescence Spectrometer
LUMINA 3500
New
Portable Tube Luminometer
Junior LB 9509
New
Coagulation Analyzer
DIAcheck C1

Print article
IIR Middle East

Channels

Molecular Diagnostics

view channel
Illustration

Point-of-Care Lateral Flow Test Detects Bladder Cancer Using Urine Sample within Minutes

A breakthrough diagnostics platform uses a multiplexed lateral flow assay that detects 10 bladder cancer biomarkers from a urine sample in either laboratory or point-of-care settings. SCIENION (Berlin,... Read more

Hematology

view channel
Image: Bone marrow aspirate from a patient with Acute Myeloid Leukemia: Blasts are the predominant population and have a high nuclear to cytoplasmic ratio and generally lack granules. (Photo courtesy of Professor Peter G. Maslak, MD)

Cord Blood and Matched Related Donor Transplantation Compared in Acute Myeloid Leukemia

The prognosis of primary refractory and relapsed acute myeloid leukemia is poor, with a five-year overall survival of less than 10%. Allogeneic hematopoietic stem cell transplantation (HSCT) is the only... Read more

Industry

view channel
Illustration

Global Immunofluorescence Assay (IFA) Market to Surpass USD 4 Billion by 2028 Due to Growing Burden of Infectious Diseases

The global immunofluorescence assay (IFA) market is expected to reach USD 4.01 billion by 2028, driven by the increasing global healthcare burden of chronic and infectious diseases, rising application... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.